Dublin, Feb. 05, 2020 (GLOBE NEWSWIRE) -- The "3rd Annual Next-Gen Immuno-Oncology Congress" conference has been added to ResearchAndMarkets.com's offering.

This congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, monoclonal antibody & Immune Checkpoint Inhibitors.

The congress would also focus on various combination strategies, brain-storming on cancer biomarker and vaccine research, collaborating on pre-clinical and translational immune-oncology developments, and personalized cancer immunotherapy

Key Highlights

• Immune Checkpoint Inhibitors and Combinations
• Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
• Monoclonal Antibody & Cellular Therapy
• Neoantigens in personalized Cancer Immunotherapy
• Biomarkers and Cancer Vaccines
• Developments in CAR-T Cellular Therapy
• Oncolytic Viral Therapy & Personalized Medicine
• Engineering Cellular Therapies Beyond Traditional Tumor Antigens
• Combination Therapies in I/O

What makes I-O transformative? Innovative approaches in patient selection, use of combinations, and sequencing of therapies lead to more patients benefitting from I-O therapy, expanding its potential impact and this also makes it more promising - from the basics of immunotherapies to the latest research results.

The rapid development of immuno-oncology (I-O) therapies has transformed the treatment landscape and brightened the long-term outlook for many patients with advanced cancer.

Why Attend?

• Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
• Find out new case studies of immune-oncology projects in development
• Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
• Explore the latest platforms and technologies on the market for development
• Discuss the best tool for your research in immune-oncology
• Share your work and achievements with your industry peers in the Poster Sessions

Speakers

• Dave Wustrow: Senior VP Discovery and Preclinical Development, RAPT Therapeutics
• Darrell Borger: Associate Director, Translational Sciences, ODDU, Takeda
• Robert Petit: Chief Scientific Officer, Carisma Therapeutics
• Nuzhat Pathan: Director, Early Development, Translational and Immuno-Oncology, Pfizer
• Philip Arlen: Chief Scientific Officer, Senior Vice President, Diverse Biotech
• Nathaniel Wang: Oncology Vaccines Project Leader, Janssen, Pharmaceutical Companies of Johnson and Johnson
• Shailesh Maingi: Founder and CEO, Kineticos Life Sciences
• Soldano Ferrone: Professor of Surgery, Harvard University, USA

For more information about this conference visit https://www.researchandmarkets.com/r/9vcsad

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900